Skip to content
BiologicalX

Comparison

Hexarelin vs Nicotinamide Riboside

Side-by-side of Hexarelin and Nicotinamide Riboside. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Hexarelin

  • Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
  • Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
  • Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
  • More cortisol and prolactin elevation than GHRP-2 or ipamorelin
  • Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
  • Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Nicotinamide Riboside

  • Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
  • Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
  • Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
  • Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
  • Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
  • Larger human safety database than NMN; comparable mechanistic effects

Side-by-side

Attribute Hexarelin Nicotinamide Riboside
Category peptide supplement
Also known as Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 NR, Niagen, nicotinamide riboside chloride
Half-life (hr) 1 8
Typical dose (mg) 0.1 500
Dosing frequency 1-2x daily daily, typically morning
Routes subcutaneous, intranasal, intravenous oral
Onset (hr) 0.25 1
Peak (hr) 0.5 4
Molecular weight 887.04 255.25
Molecular formula C47H58N12O6 C11H15N2O5
Mechanism Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38.
Legal status Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA OTC dietary supplement
WADA status banned allowed
DEA / Rx Not scheduled (research chemical) OTC supplement
Pregnancy Insufficient data; not recommended Insufficient data at supplement doses
CAS 140703-51-1 1341-23-7
PubChem CID 3037387 439924
Wikidata Q5743550 Q3343054

Safety profile

Hexarelin

Common side effects

  • water retention
  • vivid dreams
  • head pressure or flushing
  • transient lethargy
  • tingling at injection site
  • moderate hunger

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • prolactin-sensitive states

Interactions

  • CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: amplify cortisol load; blunt GH response(moderate)

Nicotinamide Riboside

Common side effects

  • mild GI upset (rare)
  • headache (rare)

Contraindications

  • pregnancy / lactation (insufficient data)
  • active cancer (theoretical, no contraindicating data)

Interactions

  • pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
  • TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)

Which Should You Take?

Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.

Edge case: If you want to avoid research-only / gray-market sourcing, Nicotinamide Riboside is the more accessible choice.

Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Hexarelin and Nicotinamide Riboside?

Hexarelin and Nicotinamide Riboside differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Hexarelin or Nicotinamide Riboside?

Hexarelin half-life is 1 hours; Nicotinamide Riboside half-life is 8 hours.

Can you stack Hexarelin with Nicotinamide Riboside?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper